Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
A five-day inspection was concluded successfully with no critical and no major observations raised
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Both organisations enter into a long- term collaboration to expand patient access in India
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Subscribe To Our Newsletter & Stay Updated
